Share Price and Basic Stock Data
Last Updated: January 29, 2026, 5:51 pm
| PEG Ratio | 1.24 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Alpa Laboratories Ltd operates in the pharmaceuticals sector, focusing on the manufacturing and distribution of various pharmaceutical products. As of the latest market data, the company’s stock price stood at ₹63.6, with a market capitalization of ₹134 Cr. The company has demonstrated fluctuating revenue trends, with sales reported at ₹112 Cr for FY 2022 and declining to ₹93 Cr in FY 2023. However, the trailing twelve months (TTM) figures indicate a recovery, stabilizing at ₹110 Cr. Quarterly sales have varied significantly, with the highest sales recorded at ₹32.39 Cr in September 2023, followed by a projected decline to ₹21.44 Cr in June 2024. The sales growth trajectory reflects both seasonal variations and operational challenges, with the overall sales growth from ₹13.54 Cr in September 2022 to ₹32.39 Cr in September 2023 indicating potential recovery in demand.
Profitability and Efficiency Metrics
Alpa Laboratories reported a net profit of ₹19 Cr, translating to a P/E ratio of 7.11, which suggests the stock is undervalued compared to industry averages. The return on equity (ROE) stood at 11.5%, while the return on capital employed (ROCE) was recorded at 15%. The operating profit margin (OPM) exhibited volatility, with a negative margin of -11.20% in the latest quarter. Notably, during FY 2023, OPM peaked at 31.76% in March 2023 before declining again. The interest coverage ratio (ICR) was robust at 121.23, indicating strong earnings relative to interest expenses. However, the cash conversion cycle (CCC) increased to 150 days, suggesting potential inefficiencies in managing working capital, which may impact liquidity if not addressed.
Balance Sheet Strength and Financial Ratios
The balance sheet of Alpa Laboratories reflects a conservative financial structure, with total borrowings standing at ₹2 Cr against reserves of ₹173 Cr, indicating a strong capital base. The current ratio is reported at 4.12, significantly above the typical sector benchmark of 1.5, suggesting excellent short-term liquidity. The debt-to-equity ratio is negligible at 0.00, showcasing minimal reliance on external debt. However, the company’s asset turnover ratio has declined to 0.55%, which may indicate inefficiencies in asset utilization compared to the sector average. The price-to-book value (P/BV) ratio is recorded at 1.28x, slightly above the typical range, reflecting a premium valuation relative to its net assets. Additionally, the enterprise value (EV) of ₹216.89 Cr points to a market perception of the company’s growth potential.
Shareholding Pattern and Investor Confidence
Alpa Laboratories has a stable shareholding structure, with promoters holding 57.29% of the equity, ensuring strong control over the company’s strategic direction. The public holds 42.36% of the shares, indicating reasonable retail investor interest, but foreign institutional investments (FIIs) are relatively low at 0.35%. The number of shareholders decreased from 19,094 in December 2022 to 18,542 by September 2025, which may reflect concerns over the company’s performance or market conditions. The absence of dividend payouts since March 2014 suggests a focus on reinvestment for growth rather than returning capital to shareholders. This retention strategy could be perceived positively if it translates into improved operational performance and market position.
Outlook, Risks, and Final Insight
The outlook for Alpa Laboratories hinges on its ability to stabilize revenue and improve profitability metrics. The company faces risks from fluctuating sales and operational inefficiencies reflected in high CCC and declining OPM. Additionally, the absence of significant institutional investment may limit growth opportunities and market perception. However, strengths such as a robust balance sheet, low debt levels, and a high ICR provide a cushion against market volatility. If the company effectively manages operational challenges and leverages its strong capital base for strategic investments, it could enhance profitability and shareholder value. Conversely, persistent inefficiencies and failure to adapt to market demands may hinder growth prospects. Investors should monitor the company’s performance in upcoming quarters for signs of recovery and operational improvements.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 123 Cr. | 97.4 | 197/84.3 | 27.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,370 Cr. | 310 | 479/192 | 69.8 | 24.3 | 0.22 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.0 Cr. | 44.5 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 69.7 Cr. | 47.6 | 47.6/17.0 | 166 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,391.12 Cr | 1,073.18 | 47.27 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.54 | 27.31 | 29.16 | 25.43 | 32.39 | 27.31 | 23.61 | 21.44 | 24.94 | 26.15 | 39.11 | 19.11 | 25.63 |
| Expenses | 19.28 | 24.68 | 19.90 | 26.58 | 29.07 | 24.85 | 20.10 | 20.90 | 21.67 | 25.41 | 39.47 | 18.69 | 28.50 |
| Operating Profit | -5.74 | 2.63 | 9.26 | -1.15 | 3.32 | 2.46 | 3.51 | 0.54 | 3.27 | 0.74 | -0.36 | 0.42 | -2.87 |
| OPM % | -42.39% | 9.63% | 31.76% | -4.52% | 10.25% | 9.01% | 14.87% | 2.52% | 13.11% | 2.83% | -0.92% | 2.20% | -11.20% |
| Other Income | 6.38 | 2.69 | -0.76 | 4.47 | 2.95 | 3.55 | 3.97 | 5.18 | 6.91 | 8.80 | 3.24 | 11.96 | 3.69 |
| Interest | 0.08 | 0.07 | 0.04 | 0.02 | 0.04 | 0.03 | 0.30 | 0.05 | 0.06 | 0.10 | 0.05 | 0.05 | 0.05 |
| Depreciation | 0.36 | 0.10 | 0.53 | 0.28 | 0.49 | 0.66 | 0.52 | 0.54 | 0.53 | 0.55 | 0.58 | 0.55 | 0.67 |
| Profit before tax | 0.20 | 5.15 | 7.93 | 3.02 | 5.74 | 5.32 | 6.66 | 5.13 | 9.59 | 8.89 | 2.25 | 11.78 | 0.10 |
| Tax % | 0.00% | 0.00% | 41.74% | 0.00% | 0.00% | 14.85% | 46.70% | 0.00% | 20.44% | 0.00% | 186.67% | 0.00% | 0.00% |
| Net Profit | 0.20 | 5.14 | 4.62 | 3.03 | 5.74 | 4.53 | 3.55 | 5.12 | 7.63 | 8.89 | -1.95 | 11.78 | 0.10 |
| EPS in Rs | 0.10 | 2.44 | 2.20 | 1.44 | 2.73 | 2.15 | 1.69 | 2.43 | 3.63 | 4.23 | -0.93 | 5.60 | 0.05 |
Last Updated: January 2, 2026, 1:04 pm
Below is a detailed analysis of the quarterly data for Alpa Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 25.63 Cr.. The value appears strong and on an upward trend. It has increased from 19.11 Cr. (Jun 2025) to 25.63 Cr., marking an increase of 6.52 Cr..
- For Expenses, as of Sep 2025, the value is 28.50 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.69 Cr. (Jun 2025) to 28.50 Cr., marking an increase of 9.81 Cr..
- For Operating Profit, as of Sep 2025, the value is -2.87 Cr.. The value appears to be declining and may need further review. It has decreased from 0.42 Cr. (Jun 2025) to -2.87 Cr., marking a decrease of 3.29 Cr..
- For OPM %, as of Sep 2025, the value is -11.20%. The value appears to be declining and may need further review. It has decreased from 2.20% (Jun 2025) to -11.20%, marking a decrease of 13.40%.
- For Other Income, as of Sep 2025, the value is 3.69 Cr.. The value appears to be declining and may need further review. It has decreased from 11.96 Cr. (Jun 2025) to 3.69 Cr., marking a decrease of 8.27 Cr..
- For Interest, as of Sep 2025, the value is 0.05 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.05 Cr..
- For Depreciation, as of Sep 2025, the value is 0.67 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.55 Cr. (Jun 2025) to 0.67 Cr., marking an increase of 0.12 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.10 Cr.. The value appears to be declining and may need further review. It has decreased from 11.78 Cr. (Jun 2025) to 0.10 Cr., marking a decrease of 11.68 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is 0.10 Cr.. The value appears to be declining and may need further review. It has decreased from 11.78 Cr. (Jun 2025) to 0.10 Cr., marking a decrease of 11.68 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.05. The value appears to be declining and may need further review. It has decreased from 5.60 (Jun 2025) to 0.05, marking a decrease of 5.55.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 56 | 57 | 53 | 63 | 62 | 77 | 85 | 97 | 112 | 93 | 109 | 110 | 110 |
| Expenses | 51 | 54 | 47 | 56 | 57 | 76 | 79 | 90 | 101 | 85 | 100 | 105 | 112 |
| Operating Profit | 6 | 3 | 7 | 7 | 4 | 1 | 6 | 8 | 11 | 8 | 9 | 5 | -2 |
| OPM % | 10% | 6% | 13% | 11% | 7% | 2% | 7% | 8% | 10% | 9% | 8% | 5% | -2% |
| Other Income | 1 | 2 | 6 | 4 | 5 | 5 | 0 | 4 | 11 | 9 | 14 | 23 | 28 |
| Interest | 2 | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 9 | 6 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 |
| Profit before tax | -5 | -3 | 11 | 9 | 7 | 5 | 5 | 11 | 20 | 16 | 21 | 26 | 23 |
| Tax % | 4% | -48% | 27% | 34% | 27% | 36% | 20% | 33% | 28% | 21% | 19% | 24% | |
| Net Profit | -5 | -1 | 8 | 6 | 5 | 3 | 4 | 7 | 14 | 13 | 17 | 20 | 19 |
| EPS in Rs | -2.45 | -0.67 | 3.68 | 2.85 | 2.27 | 1.40 | 1.94 | 3.45 | 6.72 | 6.00 | 7.98 | 9.35 | 8.95 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 80.00% | 900.00% | -25.00% | -16.67% | -40.00% | 33.33% | 75.00% | 100.00% | -7.14% | 30.77% | 17.65% |
| Change in YoY Net Profit Growth (%) | 0.00% | 820.00% | -925.00% | 8.33% | -23.33% | 73.33% | 41.67% | 25.00% | -107.14% | 37.91% | -13.12% |
Alpa Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 0% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 55% |
| 5 Years: | 30% |
| 3 Years: | 36% |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 27% |
| 3 Years: | 15% |
| 1 Year: | -8% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 9% |
| 3 Years: | 11% |
| Last Year: | 11% |
Last Updated: September 4, 2025, 11:00 pm
Balance Sheet
Last Updated: January 7, 2026, 3:21 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 67 | 66 | 73 | 77 | 82 | 85 | 89 | 96 | 111 | 124 | 141 | 161 | 173 |
| Borrowings | 23 | 29 | 24 | 11 | 6 | 2 | 0 | 0 | 6 | 3 | 5 | 0 | 2 |
| Other Liabilities | 15 | 13 | 27 | 20 | 17 | 21 | 21 | 33 | 28 | 30 | 25 | 51 | 52 |
| Total Liabilities | 127 | 128 | 145 | 129 | 127 | 129 | 131 | 150 | 165 | 178 | 192 | 233 | 248 |
| Fixed Assets | 73 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 9 | 7 | 11 | 21 | 21 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 10 | 22 | 23 | 41 | 59 | 68 | 62 | 86 | 90 | 109 | 129 | 157 |
| Other Assets | 54 | 113 | 118 | 100 | 79 | 64 | 56 | 80 | 70 | 81 | 72 | 83 | 70 |
| Total Assets | 127 | 128 | 145 | 129 | 127 | 129 | 131 | 150 | 165 | 178 | 192 | 233 | 248 |
Below is a detailed analysis of the balance sheet data for Alpa Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For Reserves, as of Sep 2025, the value is 173.00 Cr.. The value appears strong and on an upward trend. It has increased from 161.00 Cr. (Mar 2025) to 173.00 Cr., marking an increase of 12.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 52.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 51.00 Cr. (Mar 2025) to 52.00 Cr., marking an increase of 1.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 248.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 233.00 Cr. (Mar 2025) to 248.00 Cr., marking an increase of 15.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 157.00 Cr.. The value appears strong and on an upward trend. It has increased from 129.00 Cr. (Mar 2025) to 157.00 Cr., marking an increase of 28.00 Cr..
- For Other Assets, as of Sep 2025, the value is 70.00 Cr.. The value appears to be declining and may need further review. It has decreased from 83.00 Cr. (Mar 2025) to 70.00 Cr., marking a decrease of 13.00 Cr..
- For Total Assets, as of Sep 2025, the value is 248.00 Cr.. The value appears strong and on an upward trend. It has increased from 233.00 Cr. (Mar 2025) to 248.00 Cr., marking an increase of 15.00 Cr..
Notably, the Reserves (173.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -17.00 | -26.00 | -17.00 | -4.00 | -2.00 | -1.00 | 6.00 | 8.00 | 5.00 | 5.00 | 4.00 | 5.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 130 | 156 | 234 | 169 | 151 | 141 | 105 | 133 | 124 | 186 | 138 | 155 |
| Inventory Days | 148 | 76 | 196 | 131 | 140 | 105 | 90 | 102 | 81 | 84 | 73 | 92 |
| Days Payable | 121 | 91 | 244 | 140 | 130 | 99 | 98 | 152 | 78 | 100 | 63 | 97 |
| Cash Conversion Cycle | 157 | 141 | 187 | 160 | 161 | 148 | 97 | 83 | 127 | 170 | 149 | 150 |
| Working Capital Days | 65 | -4 | 224 | 197 | 204 | 189 | 121 | 137 | 124 | 150 | 132 | 108 |
| ROCE % | -3% | 0% | 10% | 11% | 7% | 4% | 7% | 7% | 9% | 11% | 14% | 15% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 9.34 | 8.01 | 5.88 | 6.70 | 3.44 |
| Diluted EPS (Rs.) | 9.34 | 8.01 | 5.88 | 6.70 | 3.44 |
| Cash EPS (Rs.) | 10.32 | 8.90 | 6.61 | 7.48 | 4.03 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 81.48 | 72.20 | 63.96 | 57.85 | 51.16 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 81.48 | 72.20 | 63.96 | 57.85 | 51.16 |
| Revenue From Operations / Share (Rs.) | 53.45 | 51.68 | 44.18 | 53.36 | 46.36 |
| PBDIT / Share (Rs.) | 13.36 | 10.93 | 8.29 | 10.19 | 5.75 |
| PBIT / Share (Rs.) | 12.31 | 10.00 | 7.66 | 9.40 | 5.16 |
| PBT / Share (Rs.) | 12.20 | 9.83 | 7.55 | 9.30 | 5.13 |
| Net Profit / Share (Rs.) | 9.27 | 7.97 | 5.98 | 6.70 | 3.44 |
| NP After MI And SOA / Share (Rs.) | 9.27 | 7.97 | 5.98 | 6.70 | 3.44 |
| PBDIT Margin (%) | 24.98 | 21.14 | 18.76 | 19.09 | 12.39 |
| PBIT Margin (%) | 23.03 | 19.35 | 17.33 | 17.61 | 11.13 |
| PBT Margin (%) | 22.82 | 19.01 | 17.09 | 17.42 | 11.05 |
| Net Profit Margin (%) | 17.34 | 15.42 | 13.53 | 12.55 | 7.42 |
| NP After MI And SOA Margin (%) | 17.34 | 15.42 | 13.53 | 12.55 | 7.42 |
| Return on Networth / Equity (%) | 11.37 | 11.04 | 9.34 | 11.57 | 6.73 |
| Return on Capital Employeed (%) | 14.72 | 13.63 | 11.90 | 15.97 | 10.07 |
| Return On Assets (%) | 8.76 | 9.19 | 7.52 | 9.07 | 5.16 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.00 | 0.03 | 0.01 | 0.04 | 0.00 |
| Asset Turnover Ratio (%) | 0.55 | 0.62 | 0.57 | 0.73 | 0.71 |
| Current Ratio (X) | 4.12 | 5.74 | 4.67 | 4.43 | 3.73 |
| Quick Ratio (X) | 3.74 | 5.25 | 4.28 | 3.93 | 3.22 |
| Inventory Turnover Ratio (X) | 7.18 | 8.27 | 3.73 | 3.96 | 3.73 |
| Interest Coverage Ratio (X) | 121.23 | 64.02 | 78.01 | 97.84 | 155.24 |
| Interest Coverage Ratio (Post Tax) (X) | 85.14 | 47.71 | 57.27 | 65.32 | 94.03 |
| Enterprise Value (Cr.) | 216.89 | 179.04 | 106.65 | 149.57 | 65.56 |
| EV / Net Operating Revenue (X) | 1.93 | 1.65 | 1.15 | 1.33 | 0.67 |
| EV / EBITDA (X) | 7.72 | 7.79 | 6.11 | 6.98 | 5.42 |
| MarketCap / Net Operating Revenue (X) | 1.95 | 1.61 | 1.22 | 1.30 | 0.77 |
| Price / BV (X) | 1.28 | 1.16 | 0.84 | 1.20 | 0.70 |
| Price / Net Operating Revenue (X) | 1.95 | 1.61 | 1.22 | 1.30 | 0.77 |
| EarningsYield | 0.08 | 0.09 | 0.11 | 0.09 | 0.09 |
After reviewing the key financial ratios for Alpa Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 9.34. This value is within the healthy range. It has increased from 8.01 (Mar 24) to 9.34, marking an increase of 1.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 9.34. This value is within the healthy range. It has increased from 8.01 (Mar 24) to 9.34, marking an increase of 1.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.32. This value is within the healthy range. It has increased from 8.90 (Mar 24) to 10.32, marking an increase of 1.42.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 81.48. It has increased from 72.20 (Mar 24) to 81.48, marking an increase of 9.28.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 81.48. It has increased from 72.20 (Mar 24) to 81.48, marking an increase of 9.28.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 53.45. It has increased from 51.68 (Mar 24) to 53.45, marking an increase of 1.77.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.36. This value is within the healthy range. It has increased from 10.93 (Mar 24) to 13.36, marking an increase of 2.43.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.31. This value is within the healthy range. It has increased from 10.00 (Mar 24) to 12.31, marking an increase of 2.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 12.20. This value is within the healthy range. It has increased from 9.83 (Mar 24) to 12.20, marking an increase of 2.37.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 9.27. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 9.27, marking an increase of 1.30.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 9.27. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 9.27, marking an increase of 1.30.
- For PBDIT Margin (%), as of Mar 25, the value is 24.98. This value is within the healthy range. It has increased from 21.14 (Mar 24) to 24.98, marking an increase of 3.84.
- For PBIT Margin (%), as of Mar 25, the value is 23.03. This value exceeds the healthy maximum of 20. It has increased from 19.35 (Mar 24) to 23.03, marking an increase of 3.68.
- For PBT Margin (%), as of Mar 25, the value is 22.82. This value is within the healthy range. It has increased from 19.01 (Mar 24) to 22.82, marking an increase of 3.81.
- For Net Profit Margin (%), as of Mar 25, the value is 17.34. This value exceeds the healthy maximum of 10. It has increased from 15.42 (Mar 24) to 17.34, marking an increase of 1.92.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 17.34. This value is within the healthy range. It has increased from 15.42 (Mar 24) to 17.34, marking an increase of 1.92.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.37. This value is below the healthy minimum of 15. It has increased from 11.04 (Mar 24) to 11.37, marking an increase of 0.33.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.72. This value is within the healthy range. It has increased from 13.63 (Mar 24) to 14.72, marking an increase of 1.09.
- For Return On Assets (%), as of Mar 25, the value is 8.76. This value is within the healthy range. It has decreased from 9.19 (Mar 24) to 8.76, marking a decrease of 0.43.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.55. It has decreased from 0.62 (Mar 24) to 0.55, marking a decrease of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 4.12. This value exceeds the healthy maximum of 3. It has decreased from 5.74 (Mar 24) to 4.12, marking a decrease of 1.62.
- For Quick Ratio (X), as of Mar 25, the value is 3.74. This value exceeds the healthy maximum of 2. It has decreased from 5.25 (Mar 24) to 3.74, marking a decrease of 1.51.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.18. This value is within the healthy range. It has decreased from 8.27 (Mar 24) to 7.18, marking a decrease of 1.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 121.23. This value is within the healthy range. It has increased from 64.02 (Mar 24) to 121.23, marking an increase of 57.21.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 85.14. This value is within the healthy range. It has increased from 47.71 (Mar 24) to 85.14, marking an increase of 37.43.
- For Enterprise Value (Cr.), as of Mar 25, the value is 216.89. It has increased from 179.04 (Mar 24) to 216.89, marking an increase of 37.85.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.93. This value is within the healthy range. It has increased from 1.65 (Mar 24) to 1.93, marking an increase of 0.28.
- For EV / EBITDA (X), as of Mar 25, the value is 7.72. This value is within the healthy range. It has decreased from 7.79 (Mar 24) to 7.72, marking a decrease of 0.07.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 1.95, marking an increase of 0.34.
- For Price / BV (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has increased from 1.16 (Mar 24) to 1.28, marking an increase of 0.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 1.95, marking an increase of 0.34.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has decreased from 0.09 (Mar 24) to 0.08, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Alpa Laboratories Ltd:
- Net Profit Margin: 17.34%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.72% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.37% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 85.14
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.74
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 7.29 (Industry average Stock P/E: 47.27)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 17.34%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 33/2, Pigdamber, A.B.Road, Rau, Indore Madhya Pradesh 453446 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mahendra Singh Chawla | Chairman |
| Mr. Paresh Chawla | Managing Director |
| Mr. Pravin Shah | Director |
| Mr. Vitthal Kothana | Director |
| Mr. Shitul Shah | Director |
| Mrs. Jyoti Jain | Independent Director |
| Mr. Sanket Baheti | Independent Director |
| Mr. Pratik Shah | Independent Director |
| Mrs. Pratibha Lunawat | Independent Director |
| Mr. Sunil Kumar Valecha | Independent Director |
FAQ
What is the intrinsic value of Alpa Laboratories Ltd?
Alpa Laboratories Ltd's intrinsic value (as of 29 January 2026) is ₹66.65 which is 2.70% higher the current market price of ₹64.90, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹137 Cr. market cap, FY2025-2026 high/low of ₹125/61.0, reserves of ₹173 Cr, and liabilities of ₹248 Cr.
What is the Market Cap of Alpa Laboratories Ltd?
The Market Cap of Alpa Laboratories Ltd is 137 Cr..
What is the current Stock Price of Alpa Laboratories Ltd as on 29 January 2026?
The current stock price of Alpa Laboratories Ltd as on 29 January 2026 is ₹64.9.
What is the High / Low of Alpa Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Alpa Laboratories Ltd stocks is ₹125/61.0.
What is the Stock P/E of Alpa Laboratories Ltd?
The Stock P/E of Alpa Laboratories Ltd is 7.29.
What is the Book Value of Alpa Laboratories Ltd?
The Book Value of Alpa Laboratories Ltd is 92.0.
What is the Dividend Yield of Alpa Laboratories Ltd?
The Dividend Yield of Alpa Laboratories Ltd is 0.00 %.
What is the ROCE of Alpa Laboratories Ltd?
The ROCE of Alpa Laboratories Ltd is 15.0 %.
What is the ROE of Alpa Laboratories Ltd?
The ROE of Alpa Laboratories Ltd is 11.5 %.
What is the Face Value of Alpa Laboratories Ltd?
The Face Value of Alpa Laboratories Ltd is 10.0.